Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 6/20 | 0.45 |
| ▸ | CTSL | P07711 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | TACR3 | P29371 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31414906 | 1.00 | FABP4 (0.45) | FABP4CTSLMAPK1FABP5CTSB | |
| SCHEMBL31414925 | 0.82 | OPRM1 (0.42) | CTSLCTSBCTSSCTSK | |
| SCHEMBL31414922 | 0.82 | OPRM1 (0.42) | CTSLCTSBCTSSCTSK | |
| SCHEMBL16989172 | 0.81 | TACR3 (0.49) | CTSLMAPK1CTSSCTSKTACR3 | |
| SCHEMBL16989173 | 0.81 | TACR3 (0.49) | CTSLMAPK1CTSSCTSKTACR3 | |
| SCHEMBL31414948 | 0.77 | FABP4 (0.41) | FABP4FABP5 | |
| SCHEMBL13624184 | 0.77 | CTSL (0.42) | FABP4CTSLFABP5CTSBCTSS | |
| SCHEMBL4368196 | 0.75 | CTSK (0.42) | FABP4CTSLFABP5CTSBCTSS | |
| SCHEMBL250886 | 0.74 | TACR3 (0.49) | CTSLCTSSCTSKTACR3 | |
| SCHEMBL31414932 | 0.73 | FABP4 (0.45) | FABP4CTSLFABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250026745-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | MIRUM PHARMACEUTICALS, INC. | 2025-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026745-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | HSD17B13, HSD17B1, HSD17B3 | FABP4 1043/4885CTSL 279/4885MAPK1 3042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.